TetraPharma Royalty Corp. entered into an agreement to acquire TetraPharma (Canada) Ltd. from Instadose Pharma Corp. (OTCPK:INSD) for $0.0001 million on July 4, 2023. The purchase price to be payable by TetraPharma in connection with the purchase of Instadose Canada shall consist of the amount of $0.0001 million and the assumption and satisfaction of all liabilities of the Company by TetraPharma. All shareholders of Instadose Pharma will be provided with the opportunity to exchange their presently held shares of common stock of Instadose Pharma for newly issued shares of common stock of TetraPharma on a one for-one basis. Instadose Canada will continue its own business operations as usual. As of July 6, 2023, Instadose Pharma has secured Shareholder Approval. The closing of this transaction shall take place on the 21st calendar day after the date when Instadose Pharma files with the U.S. Securities and Exchange Commission an information statement pursuant.

TetraPharma Royalty Corp. acquired TetraPharma (Canada) Ltd. from Instadose Pharma Corp. (OTCPK:INSD) on September 19, 2023.